Skip to main content

Table 3 Predictors of RHI change after 6 months of antirheumatic treatment in patients with ED

From: Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis

  Unadjusted Adjusted
  Beta P 95% CI Beta P 95% CI
Female gender 0.492 0.011 0.118 to 0.865 0.621 0.004 0.220 to 1.022
Age –0.004 0.669 –0.024 to 0.016 –0.001 0.919 –0.021 to 0.019
Anti-TNF ± MTX –0.505 0.008 –0.866 to –0.143 –0.448 0.032 –0.855 to –0.041
RDD –0.026 0.033 –0.049 to –0.002 –0.024 0.068 –0.050 to 0.002
PsA –0.067 0.779 –0.550 to 0.416 0.064 0.733 –0.386 to 0.514
AS –0.267 0.242 –0.722 to 0.188 0.219 0.419 –0.327 to 0.765
CRP –0.004 0.523 –0.017 to 0.009    
ESR –0.002 0.771 –0.017 to 0.013    
PTX3 –0.071 0.255 –0.194 to 0.053    
PGA 0.008 0.160 –0.003 to 0.019    
PtGA –0.001 0.824 –0.008 to 0.006    
MHAQ –0.328 0.332 –1.006 to 0.349    
NSJ –0.150 0.050 –0.299 to 0.000    
  1. Comparators: female gender versus male gender, anti-TNF ± MTX versus MTX monotherapy
  2. Statistically significant differences are shown in bold typeface
  3. anti-TNF anti-tumor necrosis factor, AS ankylosing spondylitis, CI confidence interval, CRP C-reactive protein, ESR erythrocyte sedimentation rate, MHAQ Medical Health Assessment Questionnaire, MTX methotrexate, NSJ number of swollen joints, PGA Physicians' Global Assessment Score of Disease Activity, PsA psoriatic arthritis, PtGA Patients' Global Assessment Score of Disease Activity, PTX3 pentraxin 3, RDD rheumatic disease duration, RHI Reactive Hyperemic Index